ArticleJournal of translational medicine2026
CM512, a potentially novel IgG1-based bispecific antibody dual-targeting TSLP and IL-13, for the suppression of type 2 inflammation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity.Frontiers in immunology · 2026Trial
- Disrupting the epithelial-effector axis in type 2 inflammation: the strategic superiority of dual TSLP/IL-13 blockade in achieving immunological reset.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCM512, a novel IgG1-based 1 + 1 bispecific antibody designed with one arm targeting thymic stromal lymphopoietin (TSLP) and the other targeting interleukin-13 (IL-13), is currently under phase 2 clinical investigation for multiple autoimmune diseases. Here, we reported for the first time the translational pharmacology of CM512.
methodsWe measured the binding affinity of CM512 to each cytokine and tested its ability to block TSLP- or IL-13-mediated biological activity. CM512 was also evaluated in an OVA-induced mouse asthma model to assess its therapeutic effects on type 2 inflammation. Pharmacokinetics were characterized in cynomolgus monkeys to test its half-life.
resultsCM512 bound both TSLP and IL-13 with high affinity and effectively prevented their receptor engagement. In vitro bioassays demonstrated that CM512 potently inhibited the activation of downstream signaling pathways, cell proliferation, and the release of inflammatory factors induced by either TSLP or IL-13. Moreover, CM512 showed greater inhibition of type 2 inflammatory responses compared with single-target antibodies against TSLP or IL-13. An in vivo study further confirmed that CM512 robustly inhibited type 2 inflammatory responses and alleviated disease symptoms. Pharmacokinetic analyses revealed a circulating half-life of approximately 396 to 557 h in cynomolgus monkeys.
conclusionsOur study establishes that dual TSLP/IL-13 inhibition achieves broad suppression of type 2 inflammatory pathways, overcoming limitations of single-cytokine therapies and demonstrating greater inhibition than single blockade efficacy in type 2-driven diseases. These findings provide the first translational evidence supporting the potential of dual cytokine blockade for treating refractory type 2 inflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.